73
Participants
Start Date
February 21, 2023
Primary Completion Date
July 2, 2025
Study Completion Date
September 30, 2025
efgartigimod IV
Intravenous (IV) infusion of efgartigimod
Placebo
Intravenous (IV) infusion of placebo
Peking University Third Hospital, Beijing
The First Affiliated Hospital of Zhengzhou University, Zhengzhou
Jiangxi Provincial People's Hospital, Nanchang
Jieyang People's Hospital, Jieyang
Peking University People's Hospital, Beijing
Hunan Provincial People's Hospital, Changsha
The Second Affiliated Hospital of Chongqing Medical University, Chongqing
Fujian Medical University Union Hospital, Fujian
Guangdong Provincial People's Hospital, Guangzhou
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou
The First Affiliated Hospital,Sun Yat-sen University, Guanzhou
The First Affiliated Hospital, Zhejiang University, Hangzhou
First Affiliated Hospital of University of South China, Hengyang
The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huainan
Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan
Affiliated Hospital of Jining Medical University, Jining
Liu Zhou Works Hospital, Liuzhou
The First Affiliated Hospital of Nanchang University, Nanchang
Jiangsu Province Hospital, Nanjing
Zhongda Hospital Southeast University, Nanjing
The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning
Huashan Hospital Fudan University, Shanghai
ShengJing Hospital of China Medical University, Shenyang
Shenzhen People's Hospital, Shenzhen
The First Hospital of Hebei Medical University, Shijia Zhuang
The Second Hospital of Tianjin Medical University, Tianjin
Renmin Hospital of Wuhan University, Wuhan
Wuxi People's Hospital, Wuxi
Shaanxi Provincial Hospital of Chinese Medicine, Xi'an
The First Affiliated Hospital of Xiamen University, Xiamen
Henan Provincial People's Hospital, Zhengzhou
Lead Sponsor
Zai Lab (Shanghai) Co., Ltd.
INDUSTRY
argenx
INDUSTRY